Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 400 abstracts

no pagination
Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008 Sep;72(1):114-8.   PMCID: PMC2570743
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45.
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?. Clinical lung cancer. 2008 Mar;9(2):85-91.
Mehra R, Cohen RB. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi.   PMCID: PMC2659655
Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw #196. J Palliat Med. 2008 Sep;11(7):1039-40.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Ozols RF. Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Advances in experimental medicine and biology. 2008 Jan;622:131-43.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute. 2008 Sep 03;100(17):1204-14.   PMCID: PMC2528020
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 04;99(9):1415-25.   PMCID: PMC2576487
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb;14(3):875-82.   PMCID: PMC2643368
Sanborn RE, Lally BE. Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin. 2008 Nov;18(4):423-35.
Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1378-84.
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008 Apr;8(2):124-33.
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Uzzo RG, Haas NB, Crispen PL, Kolenko VM. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer. 2008 Apr 15;112(8):1660-71.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use drug therapy Female Male pathology Antineoplastic Agents administration & dosage Treatment Outcome Clinical Trials as Topic therapy Non-Small-Cell Lung Carcinoma Lung Neoplasms 80 and over Aged Aged metabolism Ovarian Neoplasms adverse effects Carboplatin radiotherapy physiology Antineoplastic Combined Chemotherapy Protocols Neoplasm Staging Middle Aged Adult Combined Modality Therapy drug effects mortality methods Breast Neoplasms Neoplasm Drug Resistance pharmacology Tumor Cell Line Survival Analysis epidemiology United States Apoptosis immunology Hormonal Antineoplastic Agents Paclitaxel antagonists & inhibitors Adjuvant Chemotherapy Monoclonal Antibodies Disease-Free Survival erbB-2 Receptor Mice Neoplasms analogs & Pyrimidines Inbred ICR Mice Proto-Oncogene Proteins c-akt derivatives Platelet-Derived Growth Factor alpha Receptor drug surgery Drug Delivery Systems Polyglutamic Acid Piperazines Prostatic Neoplasms genetics adverse Epidermal Growth Factor Receptor physiopathology effects Quality of Life Sexual Behavior Proto-Oncogene Proteins c-kit Anus Neoplasms Mutation Research Design diagnosis Apoptosis Regulatory Proteins Radiation Injuries Radiation-Protective Agents Colostomy Socioeconomic Factors analysis Pneumonectomy secondary Radioimmunotherapy Dimerization Age Factors analogs & derivatives Astatine Gene Amplification Time Factors Gene Expression Profiling prevention & control CA-19-9 Antigen Estrogen Replacement Therapy blood Amifostine Salivary Gland Neoplasms Biological Tumor Markers Small Interfering RNA chemically induced Cell Proliferation induced Drug Approval Jaw Adjuvant Radiotherapy Peptide Fragments IGF Type 1 Receptor Conformal Radiotherapy Fallopian Tube Neoplasms Tissue Distribution Antineoplastic Protocols Nausea Weight Loss Mediastinum Osteonecrosis enzymology Pancreatic Neoplasms Gynecologic Surgical Procedures Mitomycin Nude Mice Drug Interactions Follow-Up Studies Biological Models Pyrroles Randomized Controlled Trials as Topic Inbred BALB C Mice Vomiting Squamous Cell Carcinoma Gene Silencing Deoxycytidine Survival Rate Diphosphonates Drug Dose-Response Relationship Feasibility Studies Neoplasm Antigens Phase II Clinical Trials as Topic Deglutition Neoplastic Gene Expression Regulation Sample Size Phase III Clinical Trials as Topic Radiotherapy Hypercalcemia Cell Death Retrospective Studies chemically United States Food and Drug Administration Antineoplastic Antimetabolites Gastrointestinal Stromal Tumors Heterologous Transplantation Mass Spectrometry Mitogen-Activated Protein Kinase Kinases Fluorouracil DNA Mutational Analysis Bispecific Antibodies trends
Last updated on Wednesday, March 04, 2020